Kamada Ltd. announced it obtained a tax ruling from the Israel Tax Authority regarding its previously declared cash dividend of $0.17 per share, totaling approximately $9.8 million. The payment is scheduled for September 17, 2026, to shareholders of record as of August 27, 2026. Under the ruling, Nasdaq-listed shareholders residing in countries with tax treaties may apply for a reduced withholding tax rate by submitting documentation to processing agent IBI Trust Management by October 7, 2026. Israeli corporate shareholders may be eligible for an exemption from withholding tax. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and marketed products for rare conditions.

Kamada Ltd. declared a cash dividend of $0.17 per share, totaling approximately $9.8 million, consistent with its existing dividend policy. The payment is scheduled for September 17, 2026, to shareholders of record as of August 27, 2026. This announcement accompanies the company's report of record-high revenue and profitability for the first six months of 2026. Kamada Ltd. operates in the biopharmaceutical industry, specializing in specialty plasma-derived therapies and marketed products for rare conditions.

Kamada Ltd. reported record-high first-half 2026 revenues of $100.2 million, a 13% year-over-year increase, with second-quarter revenues reaching $54.9 million, up 23%. First-half net income rose 18% to $13.4 million ($0.23 per diluted share), while adjusted EBITDA increased 14% to $25.7 million. The company affirmed its full-year guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA. Kamada also secured a three-year, approximately $50 million strategic agreement to supply plasma to a leading biopharmaceutical company. Additionally, the filing announced that Chief Financial Officer Chaime Orlev will transition out of his role effective December 31, 2026, after nine years of service. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions.

Kamada Ltd. announced it will release financial results for the second quarter and first half ended June 30, 2026, prior to U.S. market open on August 12, 2026. Management will host a conference call at 8:30 am ET to discuss performance. This is a routine earnings announcement without specific financial figures or guidance in the filing.